株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

嚢胞性線維症:契約分析レポート

Cystic Fibrosis -deals Analytics Report, 2010 to 2019

発行 GervanoRA Data Services LLP 商品コード 816256
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
嚢胞性線維症:契約分析レポート Cystic Fibrosis -deals Analytics Report, 2010 to 2019
出版日: 2019年03月29日 ページ情報: 英文 41 Pages
概要

当レポートでは、世界における嚢胞性線維症治療に関する契約情勢について分析し、契約タイプ、契約額、地域、および仲介者に基づいた分析、年度別の分析、および主要な契約のケーススタディなどを提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 分析:契約タイプ別

  • 合意
  • コラボレーション
  • M&A
  • 融資 - 助成金・支援契約
  • ライセンシング契約
  • アライアンス契約

第4章 分析:契約額・地域別

第5章 分析:企業別

第6章 分析:年間頻度別

第7章 ケーススタディ:有望な契約トップ5

  • 契約1:ROYALTY PHARMA は嚢胞性線維症治療による33億米ドルのロイヤルティ取引を発表
  • 契約2:ASTRAZENECAは小分子抗生物質事業をPFIZERへ売却
  • 契約3:VERTEX と PARION SCIENCES は、嚢胞性線維症およびその他の肺疾患における上皮性Naチャネル (ENAC) 阻害剤の開発に向け提携
  • 契約4:VERTEX と MODERNAは嚢胞性線維症向けmRNA治療薬を発見・開発すべく独占的に契約
  • 契約5:VERTEX と CRISPR THERAPEUTICS は、遺伝子疾患の新たな治療薬の発見・開発に向けCRISPR-CAS9 遺伝子編集技術を利用すべく提携

第8章 略語

目次
Product Code: GERPD001

GervanoRA's Cystic Fibrosis Deals Activity Report, 2010-2019 has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.

GervanoRA has analyzed more than 90 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.

The report through its meticulous analysis on global therapeutic landscape of Cystic Fibrosis deals assists companies in taking future partnering decisions based on competitor's R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.

For a proper understanding, GervanoRA has segmented the report into sections based on:

  • Analytics based on deal type,
  • Analytics based on deal by value,
  • Analytics based on geography
  • Analytics based on deal maker
  • Year-by-year analytics

The report also includes case studies provided for the deals that were prominent and unique among all the deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. OTHER AVAILABLE DEALS ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

3. ANALYTICS BY DEAL TYPE

  • 3.1. CYSTIC FIBROSIS AGREEMENTS
  • 3.2. CYSTIC FIBROSIS COLLABORATIONS
  • 3.3. CYSTIC FIBROSIS MERGERS & ACQUISITIONS
  • 3.4. CYSTIC FIBROSIS FINANCING- GRANT AND FUNDING DEALS
  • 3.5. CYSTIC FIBROSIS LICENSING DEALS
  • 3.6. CYSTIC FIBROSIS ALLIANCE DEAL

4. ANALYTICS BY DEAL VALUE AND GEOGRAPHY

5. ANALYTICS BY ACTIVE PLAYERS

6. ANALYTICS BY ANNUAL FREQUENCY

7. CASE STUDIES- TOP FIVE PROMINENT DEALS

  • DEAL 1: ROYALTY PHARMA ANNOUNCES $3.3 BN ROYALTY TRANSACTION WITH CYSTIC FIBROSIS FOUNDATION THERAPEUTICS
  • DEAL 2: ASTRAZENECA TO SELL SMALL MOLECULE ANTIBIOTICS BUSINESS TO PFIZER
  • DEAL 3: VERTEX AND PARION SCIENCES ESTABLISH COLLABORATION TO DEVELOP EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITORS IN CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES
  • DEAL 4: VERTEX AND MODERNA ESTABLISH EXCLUSIVE COLLABORATION TO DISCOVER AND DEVELOP MRNA THERAPEUTICS FOR CYSTIC FIBROSIS
  • DEAL 5: VERTEX AND CRISPR THERAPEUTICS ESTABLISH COLLABORATION TO USE CRISPR-CAS9 GENE EDITING TECHNOLOGY TO DISCOVER AND DEVELOP NEW TREATMENTS FOR GENETIC DISEASES

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: MAJOR AGREEMENTS IN THE CYSTIC FIBROSIS AREA
  • TABLE 02: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 03: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 04: MAJOR FINANCING DEALS- GRANTS AND FUNDING IN THE CYSTIC FIBROSIS AREA
  • TABLE 05: MAJOR LICENSING DEALS IN THE CYSTIC FIBROSIS AREA
  • TABLE 06: TOP 10 MAJOR DEALS IN THE CYSTIC FIBROSIS AREA RANKED BY DEAL AMOUNT

LIST OF FIGURES

  • FIGURE 01: CYSTIC FIBROSIS DEALS, BY DEAL TYPE
  • FIGURE 02: CYSTIC FIBROSIS DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 03: CYCTIC FIBROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT
  • FIGURE 04: PHARMACEUTICAL COMPANIES INVOLVED IN MORE THAN A SINGLE DEAL IN CF AREA
  • FIGURE 05: NUMBER OF CYSTIC FIBROSIS DEALS, YEAR BY YEAR
  • FIGURE 06: INCREASING AGREEMENT DEALS
Back to Top